NCT05256225 2026-03-18
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Chinese University of Hong Kong
New Mexico Cancer Research Alliance
Mayo Clinic
Hebei Medical University Fourth Hospital
The Wellcome Sanger Institute
The Wellcome Sanger Institute
The Wellcome Sanger Institute
National Cancer Institute (NCI)